a Open Access Full Text Article

ORIGINAL RESEARCH

MiR-144 suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SMAD4

Min Yu* Ye Lin* Yu Zhou Haosheng Jin Baohua Hou Zhongshi Wu Zhide Li Zhixiang Jian Jian Sun

Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People's Republic of China

*These authors contributed equally to this work



Correspondence: Jian Sun Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, People's Republic of China Email sunyat1877@163.com



AcroRNAs (m.) are engaged in Background/aim: Increasing evidence show hepatocellular carcinoma (HCC). The aim of this ydy w to investigate the role of miR-144 in HCC, as well as to identify its underlying Jechan

Methods: The expression levels of mini 44 were as red multiple HCC cell lines, as We further examined the effects of miR-144 well as in liver tissues from patients of the on HCC. The molecular target of miR-144 was identified using a computer algorithm and confirmed experimentally.

Results: We found that the evels of miR 44 were frequently downregulated in human HCC tissues and cell lines, and o rexpression of miR-144 dramatically inhibited HCC metastasis, invasion, cell cycle epithelial senchyper transition, and chemoresistance. We further verified the SMAD4 as a direct target of miR-144 in HCCs. Conclusion: Tak

rexpression of miR-144 or downregulation of SMAD4 may toget ial as t peutic strategies for HCC treatment. prove b ords:

icroRN liver cancer, therapeautic target

duction Int

Key

ular carcinoma (HCC) is one of the most prevalent malignant diseases and the Hepatoc hird leading cause of cancer-related deaths. One-half of the new HCC cases and HCC hs worldwide were estimated to occur in the People's Republic of China.¹ Currently, surgical resection, liver transplantation, and radiofrequency ablation are the effective approaches for HCC treatment. The recurrence rate of HCC within 2 years in patients who received surgery exceeds 50%. Due to the late detection of the tumors and high rate of recurrence and metastasis, the prognosis of HCC is still dismal, and the 5-year survival rate for patients is less than 5%.² Therefore, further elucidation of the molecular mechanisms underlying HCC invasion and metastasis are important for the development of new therapeutic strategies for diagnosis, treatment, and prognosis of HCC.

MicroRNAs (miRNAs) are a class of small, short, and noncoding RNAs, regulating gene expression by binding to sequences in a 3'-untranslated region (3'-UTR) of the target mRNA, resulting in upregulation and downregulation of the targeted gene.^{3,4} In various human cancers, some miRNAs are often upregulated and have an oncogenic function, while most miRNAs are downregulated and may possess a tumorsuppressive activity. Accumulating evidence suggests that the abnormal expression of miRNAs is involved in the invasion and metastasis during the progression of various human cancers.

OncoTargets and Therapy 2016:9 4705-4714

© 2016 Yu et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Recent evidence indicates that miRNA expression profiling has been characterized in a variety of cancers, including breast cancer,⁵ pancreatic cancer,⁶ ovarian cancer,⁷ and HCC.3 Previous data showed that certain miRNAs are involved in the proliferation and survival of HCC, including miR-199, miR-7, miR-124, and so on. In this study, we found that the levels of a specific miRNA, miR-144, were frequently downregulated in human HCC tissues and cell lines, and overexpression of miR-144 dramatically inhibited HCC metastasis, invasion, cell cycle, epithelial-mesenchymal transition, and chemoresistance. We further verified the SMAD4 as a novel and direct target of miR-144 in HCCs. In summary, our data demonstrate that SMAD4 expression is inversely correlated to miR-144 levels in HCC tissues and cell lines, and that overexpression of miR-144 in HCC cell lines decreases SMAD4 mRNA and protein levels by directly binding to the 3'-UTR of SMAD4, which subsequently leads to downregulation of SMAD4. Therefore, our data strongly indicate that miR-144 is a tumor suppressor by targeting SMAD4 expression to modulate HCC biological behaviors. Taken together, overexpression of miR-144 or downregulation of SMAD4 may prove beneficial as therapeutic strategies for HCC treatment.

Methods

Patient selection

Samples of 100 HCC tissues were obtained om pa ents who had undergone HCC surgical resection . the Gu General Hospital. The study complete with Declaration of Helsinki and was approximity the Inst utional Ethics Committee of Guangdong General Hospital. All patients signed consent for s indicating willingness to participate, and their derstapting of the procedure and general aim of the stud. All the included patients met a: pa plogical and histologically the following cr tory of other malignant tumors, confirmed H z, no h and no neovinvant prior to the surgery.

Cell culture

The following human HCC cell lines were studied: MHCC-97H, SMMC-7221, HepG2, Huh-7, and Hep3B. The normal human liver LO2 cell line was also employed as normal control. All cells were grown in Dulbecco's Modified Eagle's Medium (Thermo Fisher Scientific, Waltham, MA, USA) and supplemented with 10% fetal bovine serum (HyClone, Logan, UT, USA) and 1% penicillin/ streptomycin.

Manipulation of miR-144 expression levels

The miR-144 mimics and negative control (micrON[™] miRNA Mimic Negative Controls) were purchased from Land (Guangzhou, Guangdong, People's Republic of China). The final concentration of transfection is 50 nM.

Cell transfections

Transfection of the miR-144 mimics was performed using Lipofectamine[®] RNAiMAX (Thermo Fisher Scientific) according to the manufacturer's instruction

RNA extraction and reactime PC analysis

Total RNA was extracted from the ll line frozen tissue specimens with TRIzol reent (dermo Fisher Scientific), and the concentration the total A was cantitated by measuring the absorb ementary DNA was generated using a miScrip, Peverse Transcription Kit (Qiagen NV, etherlands). Primers for miR-144 and the U6 Venlo nuclear RNA (snRNA) (internal control) were purchased sma Land. The expression level of miRNA was defined based fron reshold *c*le (Ct), and relative expression levels were on the cloulated using the $2^{-\Delta\Delta Ct}$ method, using the expression level nRNA as a reference gene. Each polymerase chain of eaction (PCR) was performed in triplicate. The primers for he examined genes are presented in Table 1.

Cell invasion assay

The invasion assay was performed using a transwell chamber, consisting of 8 mm membrane filter inserts (Corning Incorporated, Corning, NY, USA) coated with Matrigel (BD Biosciences, San Jose, CA, USA). Briefly, cells were trypsinized and suspended in serum-free medium. Next, 1.5×10^5 cells were added to the upper chamber, and the lower chamber was filled with medium containing 10% fetal bovine serum. After 36 hours of incubation, cells that had invaded the lower chamber were fixed with 4% paraformaldehyde, stained with hematoxylin, and counted using a microscope.

Table I Primer for qRT-PCR

hsa-miR-144	F: 5'-ACACTCCAGCTGGGTACAGTATAGATGATGTA
	R: 5'-CTCAACTGGTGTCGTGGA
U6	F: 5'-CTCGCTTCGGCAGCACA
	R: 5'-AACGCTTCACGAATTTGCGT

Abbreviation: qRT-PCR, quantitative reverse transcription polymerase chain reaction.

Wound-healing assay

Wound-healing assay was performed using HepG2 and Huh-7 cells. Cells were trypsinized and seeded in equal numbers into six-well tissue culture plates, and allowed to grow until confluent (approximately 24 hours). Following serum starvation for 24 hours, an artificial homogenous wound (scratch) was created onto the cell monolayer with a sterile 100 μ L tip. After scratching, the cells were washed with serum-free medium, complete media was added, and microscopic images (20× magnification) of the cells were collected at 0, 12, and 24 hours.

Luciferase reporter assay

Luciferase reporter assay was performed according to the manufacturer's instructions. Briefly, cells (3.5×10^4) were seeded in triplicate in 24-well plates overnight. Next, 100 ng of pGL3-*SMAD4*-3'-UTR (wild type/mutant) or control-luciferase plasmid plus 1 ng of pRL-TK renilla plasmid (#E2810; Promega, Madison, WI, USA) were transfected into the cells using Lipofectamine[®] 2000 (Thermo Fisher Scientific). Three independent experiments were performed and the data are presented as the mean \pm standard deviation (SD).

Statistical analysis

A Student's *t*-test was used to evaluate the staticical significance of the difference between two groups of due *P*-value of less than 0.05 was considered to be sufficient significant. All analyses in the present surgly were sufformed by SPSS 13.0 (SPSS Inc., Chicaro, IL, VA) statistical software package.

Results

The expression of miR-144 is frequently downregulated in LCC cell lines and tissues

ether n 144 is correlated with the To deter time w progres on of expression level of miR-144 was C cell lines, tissues, and matched with adjadetected in ver tissues obtained from 100 patients by cent nontumo. quantitative reverse transcription polymerase chain reaction (qRT-PCR). The results showed that the expression of miR-144 was dramatically decreased in various HCC cell lines, including MHCC-97H, SMMC-7221, HepG2, Huh-7, and Hep3B, compared with the normal hepatic cell line LO2 (Figure 1A). As shown in Figure 1B, the expression of miR-144 was found decreased (negative expression and low expression of miR-144) in 85.0% (85/100) of HCC

tissues compared with matched adjacent nontumor liver tissues, with an average of 5.20-fold reduction in expression (median =0.73 vs 1.52; P<0.01). No statistically significant relationships were found between miR-144 expression and any of the clinicopathological parameters except for recurrence (P=0.0041) (Table 2). Moreover, the expression of miR-144 was significantly higher in the HCC samples at early stages (TNM I and II) compared to that of the HCC samples at advanced tumor stages (TNM III) (Figure 1C).

Effect of miR-144 on the proliferation of HCC cells

To determine whether miR-14 an inhibit t proliferation of HCC cells, miR-144 mics we transfe d into HepG2 and MHCC-97H cell EdU ar lysis of nase cells showed that EdU-positive condect ased significantly after treatment mimics mpared ath mimic mock control with miR-14 in both M л 5-97Н (45. vs 27.53%, P<0.001) and 23.46%, P<0.001) (Figure 2A and B). HepG2 (49.67%) that both cells with miR-144 mimics roliferated at a slower rate than did control cells, and stastical analysis showed a significant difference after culture 4 days (gure 2C and D). The cell cycle of these cells was acceled by flow cytometry. The results showed that % of MHCC-97H and 32.74% of HepG2 cells were in S-phase, while 22.96% of MHCC-97H and 23.15% of HepG2 cells were in S-phase after treatment with miR-144 mimics (P < 0.05, Figure 2E-G). Therefore, the results indicated that miR-144 can suppress the cell cycle progression and inhibit the proliferation of HCC cells.

Effect of miR-144 on migration and invasion of HCC

To further investigate the biological significance of miR-144 in HCC, we detected the effect of miR-144 on migration and invasion of HCC cells. Wound-healing assay showed that the mobility of HepG2 and MHCC-97H cells evidently decelerated in rate in within 48 hours compared with controls (wound closure of 24.71% vs 100.00% in MHCC-97H, P<0.001; 24.01% vs 100.00% in HepG2 at 48 hours, P<0.001) (Figure 3A and B). Transwell with Matrigel showed that treatment with miR-144 led to a significant decrease in invasive potential of MHCC-97H (6.31-fold reduction, P<0.001) and HepG2 (5.14-fold reduction, P<0.001) (Figure 3C and D). Taken together, the expression of miR-144 suppresses the migration and invasion of HCC.




Figure I Downregulation of miR-144 in HCC tiss ower than the normal liver cell line LO2. The relative expression of miR-144 was normalized to Notes: (A) The relative miR-144 expression i ell lines was m the endogenous control U6 snRNA. Each san e was a red in triplicate. <0.05, **P<0.01, compared with normal liver cell line. (B) The expression level of miR-144 was decreased in 100 HCC tissues than their atched adjacer ntumor liver tissues. Each sample was analyzed in triplicate and normalized to the U6 snRNA. Data represent mean ± SD. **P<0.01, compared with rmal tissues. (**C**) T plative expression level of miR-26b was examined in normal human liver tissue (Normal), and HCC tissues at different WHO classifications. J.005; **P≤0.01. ra; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; qRT-PCR, quantitative reverse transcription polymerase chain ular carci Abbreviations: HCC, hepato idard deviation; WHO, World Health Organization. reaction; snRNA, small nuclear SD

Effect of niR-1.4 on chemoresistance and apopter's of HCC

As shown in Figh. 1A, 5-fluorouracil (5-FU) inhibited cell proliferation of both cell lines in a dose-dependent manner. The half maximal inhibitory concentration (IC_{50}) values of 5-FU were 88.56±43.29 and 10.19±3.31 mg/L after transfection by miR-144 in MHCC-97H (P<0.001), whereas IC_{50} values were 10.66±2.19 and 1.92±0.48 mg/L after transfection in HepG2 (P<0.001) (Figure 4A and B). We also detected the apoptotic population of both cell lines transfection by miR-144 by flow cytometry. The results showed that 1 mg/L 5-FU-induced apoptotic populations of MHCC-97H

and HepG2 were 56.37% and 60.15%, respectively. After transfection by miR-144, the apoptotic population reduced to 8.48 ± 0.47 (*P*<0.001) and 13.46 ± 0.52 (*P*<0.001) (Figure 4C and D). Our results generally showed that miR-144 can enhance the chemosensitivity in HCC cell lines.


Function of miR-144 in HCC cells partially attributed to targeting SMAD4


To determine the underlying mechanism by which miR-144 regulates progression and chemoresistance of HCC, we integrated bioinformatics algorithms, including miRanda, Pic-Tar, and TargetScan, to predict the potential direct target of

Table 2 Relationship between miR-144 expression and clinicopathological features of HCC patie	Table 2 Relationship	onship between miR-I	44 expression a	nd clinicopathologica	I features of HCC pat	ients
---	----------------------	----------------------	-----------------	-----------------------	-----------------------	-------

	Number of cases (%)	Expression of miR-144		
		High (15/100)	Low (85/100)	P-valu
ex				1.0000
Male	48	7	41	
Female	52	8	44	
Age (years)				0.2591
≤60	56	6	50	
>60	44	9	35	
Diameter (cm)				1.0000
≤5.0	60	9	51	
>5.0	40	6	34	
listological differentiation			_	0.1315
Well	35	2	33	
Moderate	49	9	40	
Poor	16	4		
iver cirrhosis				0.8191
Yes	35	6	29	
No	65	10	55	
Recurrence	20			0.0041
Yes	29	9	20	
No	71	6	65	
IBsAg status	70			0.6360
Positive	78 22		18	
Negative erum AFP (ng/mL)	22	4	18	0.9147
<25	19		16	0.7147
≥25	81	12	69	
	Patitis B surface antigen; HCC, hepatoce	В	■ NC ■ miR-144	
A MHCC-97H	HepG	B Bercentage of broliferation c b b c b c b c c c c c c c c	***	
А мнсс-97н	Funda in the second sec	B Bercentage of broliferation c b b c b c b c c c c c c c c	Ţ	-

Figure 2 (Continued)





miR-144. Accelling to the prediction, *SMAD4* has the putative miR-144-bind, usite that maps to the 3'-UTR. To further validate the prediction results, we constructed the luciferase reporters carrying the wild type and mutant type of *SMAD4* 3'-UTR (Figure 5A). As shown in Figure 5B, luciferase assays indicated that the wild type of 3'-UTR caused a significant reduction in luciferase activity, whereas mutation of the key seed region in the 3'-UTR of *SMAD4* showed no variations in the luciferase activity compared with the control (Figure 5B). The qRT-PCR analysis suggested that treatment by miR-144 mimics significantly repressed the expression of *SMAD4*

mRNA (Figure 5C). These findings were further verified by Western blot analysis, which indicated that treatment by miR-144 mimics markedly inhibited *SMAD4* protein level (Figure 5D). Taken together, these results strongly suggested that miR-144 could significantly suppress the expression of *SMAD4* through targeting the 3'-UTR.

To determine the correlation of miR-144 and *SMAD4* expression in clinical HCC tissues, qRT-PCR was employed to assess the expression of *SMAD4* in 100 HCC tissues. As indicated in Figure 5E, results of Spearman's rank test showed a significantly negative correlation between miR-144




Figure 3 Effect of miR-144 on growth and invasion of HCC cell in vitro. e (**B**) in MHCC H and HepG2 cell lines transfected with miR-144 mimics was Notes: (A, B) Representative images of wound-healing assay (A). The wound healing significantly decreased compared with the mimic mock control. (C, D) Representative ges (**C**) and q invaded cells in the MHCC-97H and HepG2 transfected with miR-144 was significantly deci d compar P-values were calculated using the Student's t-test. ***P<0.001. trol; h, hours. Abbreviations: HCC, hepatocellular carcinoma; SD, standard deviation; nega

and SMAD4 expression (r=-0.768, P<0J1) (Ì ure 51 Therefore, our results suggested that n 2-144 HCC development of HCC part hibiting the throu expression of SMAD4.

Discussion

More and more evid ace indicate that mixNAs are important regulators in v. ous o fular processes and are recently lating to ancer initiation, progresextensively in tigate he involvement of miRNAs sion, diag sis, ai treatm patho s is well established, as they behave in can r tumor-suppressive role depending on their as oncoge s.⁹ Dysregulation of miRNAs is often found functional tar. in HCC, and some of them have an important role in the progression and development of HCC.³ However, the role of miRNAs in the pathogenesis of HCC is still largely unclear as a single miRNA may regulate multiple target genes and a single mRNA may be regulated by various miRNAs.¹⁰ Given the complexity of the network between mRNAs and miRNAs, further studies are needed to determine the importance of miRNAs because of the potential in cancer diagnostic and prognostic value. Further understanding of the functional role

ntification (**D**) of the transwell invasion assay. The number of with the mimic mock control. Data are presented as mean \pm SD;

of miRNAs in cancer helps to better reveal the underlying mechanism of HCC pathogenesis and progression.

Previous evidence demonstrated that miR-144 expression was deceased in various cancers, including HCC, cholangiocarcinoma,¹¹ colorectal cancer,¹² bladder cancer,¹³ and thyroid cancer,¹⁴ and inversely related with cancer proliferation and metastasis. Although a previous study demonstrated that miR-144 might suppress the growth and motility of HCC cells partially by targeting E2F3, the knowledge about the role of miR-144 in HCC is still limited.¹⁵ Therefore, the present study was carried out to further investigate the functional role of miR-144 in HCC. The findings of the present study are in line with those of previous evidence, which showed the reduced expression of miR-144 in cancer cell lines and human tissues. The present study showed that decreased expression was found in HCC cell lines and human tissues, and negatively correlated with the severity and progression of HCC, suggesting that decreased expression of miR-144 correlated with the malignant potential of HCC. Therefore, we assessed the effect of miR-144 on proliferation, migration, invasion, chemoresistance, and apoptosis. Consistent with prior studies,¹⁵ we showed that upregulation




Figure 4 Effect of miR-144 on chemoresistance and apoptosis of HCC. Notes: (A, B) Cell viability were determined by MTT assays at 484 there trans lines. (C) Apoptotic population of MHCC-97H and HepG2 cell (1.5. Flow the trans Annexin V FITC/PI. Quadrants: Q1: normal cells; Q2: necret cells; Q3: the cells; mean ± SD. ***P<0.001, P-value compared with the control way.

of MHCC-97H and HepG2 cell/1.45. Flow a tometric valysis of 1 mg/L 5-FU-induced apoptosis in MHCC-97H and HepG2 cell lines using Q1: normal cells; Q2: necreal cells; Q3: ne cells; Q4: poptotic cells. (**D**) Columns, mean of three experiments. Data are presented as compared with the control of the

on of the miR-144 mimics and mimic mock control in MHCC-97H and HepG2 cell

Abbreviations: HCC, hepatocellular carcinoma; SD, dard references in FITC, fluorescein isothiocyanate; Pl, propidium iodide; NC, negative control; 5-FU, 5-fluorouracil.





Figure 5 (Continued)






Figure 5 Function of miR-144 in HCC cells partially attributed to targeting SMAD4. Notes: (A) miR-144 and its putative binding sequence in the 3'-UTR of SMAD4. The mutant SMAD4 binding site was ge ated in the comp te for the seed region nta SMAD4. of miR-144. (B) miR-144 significantly suppressed the luciferase activity that carried wild-type SMAD4 but not the mu on of miR-144 significantly Overexp decreased the mRNA levels of SMAD4 in MHCC-97H and HepG2 cell lines compared with control. (D) Overexprese of mi 44 significantly decreased the protein levels of SMAD4 in MHCC-97H and HepG2 cell lines compared with control. (E) Analysis of correlation of miR-14 d SMA ression in b tissues (two-tailed Spearman's s. **P<0.01; ***P<0.001. correlation analysis, r=-0.768; P=0.001, n=100). Data were presented as fold change of HCC tissues relation co nontumo ncent tis Abbreviations: HCC, hepatocellular carcinoma; UTR, untranslated region; 5-FU, 5-fluorouracil; NC e control; Ct, cycle.

of miR-144 can suppress the proliferation, migration, and invasion of HCC cell lines. Further, our results revealed that upregulation of miR-144 could repress cell cycle progression by inducing G0/G1 cell cycle arrest, and also could ep ance chemosensitivity and induced cancer cell apoptosis. lso. we identified SMAD4 as a novel target of miR-144 in cells. SMAD4 proved to be the key mediator sform <u>_</u>th growth factor beta (TGF- β) pathway,^{16–19} which h a centra role in the growth of hepatocytes.¹⁹ Int. reported that miR-144 is a critic regulator f the TGF- β signaling cascade and is over d in lungs h bronchiolitis obliterans syndrom which sug st an important role of miR-144 in regulati $_{2}$ TGF- β pathway. According to the previous data, SM 24 has d roles of tumor-suppressive ۰f ets in different cancers. Loss or and tumor-promoting AD_4 proved to be inversely related inactivation nosis r hcreatic incer,^{21,22} colorectal cancer,²¹ with pr ona, tother malignancies.²⁴ However, cholang arci increased expession of SMAD4 was observed in HCC16,25,26 h poor prognosis.27 and correlated

Recent evidence suggested that *SMAD4* processes a highly tumor-promoting function of *SMAD4* in HCC and might serve as an ideal therapeutic target. Therefore, *SMAD4* inhibition represents a rational and promising new approach for HCC therapy due to its unique and specific role in HCC. To validate the prediction experimentally, luciferase reporter assay was employed and the results confirmed that *SMAD4* is a target gene of miR-144. These data were further strengthened by assessment of the protein level of *SMAD4* in both

VecC cell lines treated with miR-144 mimics. Moreover, the oexpression of miR-144 and *SMAD4* was detected in HCC sues, and the results showed a significantly negative correlation between them. Taken together, these results strongly suggested that miR-144 may exert a tumor-suppressive function by repressing the expression of *SMAD4* in HCC development.

Conclusion

The results of this study strongly suggested the tumorsuppressive role of miR-144 in HCC. Moreover, the present study also demonstrated that upregulation of miR-144 leads to inhibition of cell proliferation, cell cycle progression, chemoresistance, and other malignant biological behaviors.

Acknowledgments

This study was supported by grants from the National Science Foundation of Guangdong Province, People's Republic of China (No 2014A030310073), Guangdong Provincial Science and Technology Plan projects (No 2009B080701021 and 2010B080701021), Guangdong Province Public Interest Research and Capacity - Building Projects, People's Republic of China (No 2014A020212448), and Guangzhou Science and Technology Plan of Scientific Research Projects, People's Republic of China (No 201510010286).

Disclosure

The authors report no conflicts of interest in this work.

References

- Shen G, Lin Y, Yang X, Zhang J, Xu Z, Jia H. MicroRNA-26b inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting USP9X. *BMC Cancer*. 2014;14:393.
- Hou B, Jian Z, Chen S, Ou Y, Li S, Ou J. [Expression of miR-216a in pancreatic cancer and its clinical significance]. *Nan Fang Yi Ke Da Xue Xue Bao.* 2012;32(11):1628–1631. Chinese.
- Yang J, Han S, Huang W, et al. A meta-analysis of microRNA expression in liver cancer. *PLoS One*. 2014;9(12):e114533.
- Vosa U, Kolde R, Vilo J, Metspalu A, Annilo T. Comprehensive metaanalysis of microRNA expression using a robust rank aggregation approach. *Methods Mol Biol*. 2014;1182:361–373.
- Wu J, Lu P, Yang T, Wang L. Meta-analysis of the differentially expressed breast cancer-related microRNA expression profiles. *J Obstet Gynaecol.* 2014;34(7):630–633.
- Hong TH, Park IY. MicroRNA expression profiling of diagnostic needle aspirates from surgical pancreatic cancer specimens. *Ann Surg Treat Res.* 2014;87(6):290–297.
- Sun Y, Guo F, Bagnoli M, et al. Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. *Chin J Cancer*. 2015;34(1):28–40.
- Tsai MM, Wang CS, Tsai CY, et al. Potential diagnostic, prognostic and therapeutic targets of microRNAs in human gastric cancer. *Int J Mol Sci.* 2016;17(6):945.
- Lujambio A, Lowe SW. The microcosmos of cancer. *Nature*. 2012; 482(7385):347–355.
- Hashemi GA, Burkhard FC, Rehrauer H, Aquino Fournier C, Monastyrskaya K. MicroRNA MiR-199a-5p regulates smooth muscle cell proliferation and morphology by targeting WNT2 signaling pathway. *J Biol Chem.* 2015;290(11):7067–7086.
- 11. Yang R, Chen Y, Tang C, et al. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b. *BMC Cancer*. 2014;14:917
- Zhao M, Huang J, Gui K, et al. The downregulation of miR-144 associated with the growth and invasion of osteosarcoma cells through the regulation of TAGLN expression. *Int J Mol Med* (194:34(6): 1565–1572.
- Guo Y, Ying L, Tian Y, et al. miR-144 downproduction in beases bladder cancer cell proliferation by targeting E. 2 and Wnt signaling. *FEBS J.* 2013;280(18):45312,238.
- Guan H, Liang W, Xie Z, et al. Down-reportion of mike 4 promotes thyroid cancer cell invasion by targetine 2 1 and ZEB2. *Mocrine*. 2015;48(2):566–574.

- Cao T, Li H, Hu Y, Ma D, Cai X. miR-144 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting E2F3. *Tumour Biol.* 2014;35(11):10759–10764.
- Torbenson M, Marinopoulos S, Dang DT, et al. Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling. *Hum Pathol.* 2002; 33(9):871–876.
- Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. *Oncogene*. 1999; 18(34):4879–4883.
- Lee DK, Park SH, Yi Y, et al. The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis. *Genes Dev.* 2001;15(4):455–466.
- Rossmanith W, Schulte-Hermann R. Biology of transforming growth factor beta in hepatocarcinogenesis. *Microsc Res. h.* 2001;52(4): 430–436.
- 20. Xu Z, Ramachandran S, Gunasekarah et al. Microk A-144 dvsfactor regulates the transforming grov ta signaling ascade and contributes to the developm . of bronchio oblit ins syndrome nation. Jafter human lung transpl eart Lu ansplant. 2015; 34(9):1154-1162.
- 21. Ang CW, Nedjadi Zusheik, so set al. Smart loss is associated with fewer S100A8-pointive monocy is in colorical tumors and attenuated response to S10.2, bin colorical and the relatic cancer cells. 2010;31(9): 1541–1551.
- 22. Hahn SA, Hoque AT, Markaluk CA, et al. Homozygous deletion map at 1977 arXiv pancreatic carrer. *Cancer Res.* 1996;56(3):490–494.
- 23. Jagani P, Shaukat A, Kaushal M, et al. Differing rates of loss of PC4 expression and of p53 overexpression among carcinomas of the ximal and distribute ducts. *Cancer*. 2001;91(7):1332–1341.
- 24. M. ki M, Kurger T. Role of Smad4 (DPC4) inactivation in human cance. *Biophys Res Commun.* 2003;306(4):799–804.
 - Yamazaki K, Masugi Y, Sakamoto M. Molecular pathogenesis of republic carcinoma: altering transforming growth factor-beta signaling in hepatocarcinogenesis. *Dig Dis.* 2011;29(3):284–288.
- Lu Y, Wu LQ, Li CS, Wang SG, Han B. Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis. *Hepatobiliary Pancreat Dis Int.* 2008;7(2):174–178.
- Hiwatashi K, Ueno S, Sakoda M, et al. Strong Smad4 expression correlates with poor prognosis after surgery in patients with hepatocellular carcinoma. *Ann Surg Oncol.* 2009;16(11):3176–3182.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal

Dovepress

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.